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Abstract
Background In recent years, skin reactions secondary to the use of medical devices (MD), such as allergic con-
tact dermatitis have increasingly been observed (e.g. to continuous blood sugar monitoring systems, insulin pumps,
wound dressings, medical gloves, etc.): this is regarded as a developing epidemic. Lack of labelling of the compo-
sition of MD, as well as frequent lack of cooperation of manufacturers to disclose this relevant information, even
when contacted by the clinician for the individual case of an established adverse reaction, significantly impede
patient care.
Objectives To advocate for full ingredient labelling in the implementation of EU regulation for MD.
Methods This position paper reviews the scientific literature, the current regulatory framework adopted for MD to date,
and the likely impact, including some costs data in case of the absence of such labelling.
Results Efforts made by several scientific teams, who are trying to identify the culprit of such adverse effects, either via
asking for cooperation from companies, or using costly chemical analyses of MD, can only partly, and with considerable
delay, compensate for the absence of meaningful information on the composition of MD; hence, patient management is
compromised. Indeed, without knowing the chemical substances present, physicians are unable to inform patients about
which substances they should avoid, and which alternative MD may be suitable/tolerated.
Conclusion There is an urgent need for full and accurate labelling of the chemical composition of MD in contact with
the human body.
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A medical device (MD) is defined as any instrument, equipment,
material or product intended to be used in humans for medical
purposes, the main action of which is not of pharmacological or
immunological nature.
A great number of MDs exist, ranging from simple contact
lenses and adhesive plasters to sophisticated pacemakers. As
defined in Annex VIII (Classification rules, Regulation EU 2017/
745), they are classified into 4 categories (I, IIa, IIb and III)
according to their risk level, which is based on several criteria,
including indications, invasiveness, duration of use (<1 h,
≤30 days, >30 days) and implantability, but also the risk for the
patient.
On 5 April, 2017, two new regulations for medical devices
(MD) were adopted in the European Union, in order to provide
better protection of public health and patient safety; these con-
cerned medical devices (Regulation EU 2017/745)1 and in vitro
diagnostic medical devices (Regulation EU 2017/746).2
These two regulations entered into force on 25 May, 2017,
progressively replacing the existing directives, and were sup-
posed to become fully applicable in May 2020 for medical
devices, and in May 2022 for in vitro diagnostic medical devices.3
However, due to urgent priorities related to the coronavirus cri-
sis, the Council and the Parliament adopted Regulation 2020/
5614 amending Regulation (EU) 2017/745 on medical devices
regarding application dates of certain of its provisions on 23
April, 2020. It postpones the date of application of the Medical
Devices Regulation until May 2021, whereas for the In Vitro
Diagnostic Medical Devices Regulation (IVDR, Regulation (EU)
2017/746), the corresponding date of application remains the
same (May 2022).
These regulations contain important changes to the previous
system to enable the sector to produce safer and more innovative
devices and help address future challenges.
Regarding patient benefits, the new regulations are intended
to introduce:
• ‘Better protection of public health and patient safety’, that
is stricter pre-marketing control, particularly for high-risk
devices (e.g. coloured contact lenses or equipment for lipo-
suction), strengthening of clinical evaluation and investiga-
tion and stricter requirements on the use of hazardous
substances.
• A comprehensive EU database on medical devices, a large
part of it available for the public, such as a newly introduced
summary of safety and performance for all Class III and
implantable devices.
• A new device identification system that will allow easier
traceability of medical devices.
• An ‘implant’ card for patients containing information about
implanted medical devices.
• A robust financial mechanism to ensure patients are com-
pensated in case they receive defective products.
However, despite the claim for better protection of public
health and patient safety, the two new regulations do not offer a
decisive benefit for the prevention and management of adverse
events, such as irritant and allergic contact dermatitis caused by
ingredients present in medical devices; they do not mention
their qualitative composition nor explicitly require ingredient
labelling on the packaging of MDs.
Although there is no doubt that MDs contribute to improve
the quality of clinical care, adverse reactions following their use
in patients are to be expected, including skin reactions, which
should be considered in the implementation process of the Med-
ical Device Regulation.
Indeed, case series of allergic contact dermatitis (ACD) caused
by MDs have recently been published, particularly from medical
devices in diabetic patients, such as glucose sensors and insulin
pumps. The first case caused by an insulin pump was described
in 19855 and by a glucose sensor in 2016,6 followed by a consid-
erable number of similar cases. As a result of investigative chro-
matographic analyses and the performance of patch tests in
patients to confirm sensitization, various known allergens were
identified in several types of MDs, that is ethyl cyanoacrylate,6,7
isobornyl acrylate (IBOA),8–11 N,N-dimethylacrylamide12 and
colophonium.13
As briefly illustrated above, the problem regarding the pres-
ence of allergens in MDs is not limited to devices for diabetic
patients. Many other cases of ACD from various devices have
been reported in the literature in recent years. For example,
medical dressings and adhesives containing acrylic com-
pounds,14 or foam wound dressings containing alkyl glucosides,
well-known allergens in cosmetic products,15 for which no coop-
eration from the respective manufacturers could be obtained
during the clinical investigation of patients. Surgical glues con-
taining cyanoacrylate,16 described as causes of ACD in diabetic
patients as well,7,17 MDs used in cardiology, such as silicone in
pacemakers,18 and even colophonium and herbal extracts in self-
adhesive electrocardiography electrodes19 are involved. Dental
prostheses, endoprosthesis, etc. are also concerned. Medical
gloves, labelled as medical devices and personal protective equip-
ment, used by healthcare workers containing latex and rubber
chemical accelerators are also responsible for ACD.20,21
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Publications have reported mislabelling in several products
labelled ‘accelerator-free’ gloves.22
The list of MDs causing ACD is extremely long, affects all
medical specialties, is extremely varied and ever-changing, mak-
ing it impossible to establish an exhaustive and current date list
on this subject.
Discussion
It is noteworthy to point out that labelling the list of ingredients
is an integral component of European legislation concerning
packaged foodstuffs (Regulation (EU) No. 1169/2011), medici-
nal products (Directive 2001/83/EC) and also cosmetics (Regula-
tion (EC) No. 1223/2009), which informs consumers exposed to
them, and protects them from re-exposure in case of known
allergy. Paradoxically, no equivalent provision on labelling of
components present in MDs has been laid down in the Medical
Device Regulation. From a medical point of view, it remains elu-
sive why such devices are currently not subject to a similar legis-
lation as there is no plausible substantial difference regarding
consumer or patient safety.
For consumers and patients, but also prescribers, that is medi-
cal professionals, it is important and urgent to obtain more
transparency regarding the composition of MDs. Therefore, as
medical experts and members of scientific societies specialized in
allergy and adverse skin reactions (European Society of Contact
Dermatitis, European Environmental and Contact Dermatitis
Research Group, European Academy of Dermatology and Ven-
erology, and European Academy of Allergy and Clinical
Immunology), we strongly recommend that the European Com-
mission review the current regulations for MDs with regard to
labelling of all ingredients.
Although requirements for labelling are addressed in several
sections of Regulation EU2017/745, Annex I, 10.4.5. (on label-
ling) does not mention allergenic or sensitizing components.
Yet, Annex I 23.4 (Information in the instructions for use)
states: ‘[. . .] The information shall cover, where appropriate:
-precautions related to materials incorporated into the device
[. . .] that could result in sensitization or an allergic reaction by
the patient or user’.
To comply with this claim, a specification regarding labelling
of ingredients should be included in the Question & Answer (Q
& A) list for implementation. Preferably, this should include full
labelling, but at least the following minimum requirement
‘Labelling needs to include skin (and airway) sensitizers as iden-
tified in CLP (H317) used at any stage in the production of the
medical device with body contact, with or without drugs
included’.
Although there are probably several steps at different produc-
tion sites in the manufacturing of MDs and because many rele-
vant allergens in the MDs are not yet CLP (H317) classified, we
believe that it is important to require full labelling for any
device, as is the case for pharmaceutical products and cosmetics.
Standardization in nomenclature of pharmaceutical ingredients
and certainly of cosmetic ingredients is well established.23 The
current absence of such requirements for MDs might explain
why there is an increasing tendency to market topical prepara-
tions, for example wound gels and skincare products as medical
devices, possibly in order to avoid the more restrictive regulatory
framework of the community code related to medicinal products
for human use and the cosmetic regulation.
Furthermore, with regard to information regarding materials
incorporated into the device that could result in sensitization or
an allergic reaction by the patient or user, we strongly encourage
implementation of an obligation of MD manufacturers to coop-
erate and disclose all information necessary for the management
of patients who have suffered an adverse event. This particularly
concerns full disclosure of the components (to the treating
physician) of the device that has induced the reaction in order to
carry out patch testing in case of ACD.
Instead of, or in addition to the respective specification in the
Question & Answer list for implementation as outline above, an
overarching guideline or multifaceted legislation amending the
existing Regulation EU 2017/745 in order to make ingredients in
MDs transparent (e.g. by full qualitative labelling on the pack-
age, similar to cosmetics) could endorse better protection of
public health and patient safety. Beyond the complete and pre-
cise information that could be provided, following a standard-
ized terminology such as INCI and INN, complete labelling of
MDs would contribute to reduce direct and indirect cost of ill-
ness associated with the management of allergic complications.
Moreover, based on full labelling requirements within the EU
regulation implementation, physicians prescribing MDs would
be able to identify the presence of allergens in a sensitized sub-
ject. In these cases, a safer and more suitable alternative can then
be proposed.
Such a refinement of implementation of MD-legislation is
urgently required in view of the many publications highlighting
allergic complications, including ACD, and challenges of man-
agement of adverse events following the use of MDs:
Frequent occurrence of severe chronic skin reactions
Following several isolated cases of ACD caused by MDs during
the last 5 years, the number of cases has increased considerably,
making ACD from glucose sensors a ‘hot topic’. This increasing
epidemic could easily have been limited if manufacturers had
collaborated and replaced the actual culprit ingredients. But in
practice, replacing known sensitizers with less allergy-prone
subassemblies is probably considered a delicate task and a real
challenge for manufacturers. However, due to this lack of collab-
oration, an increased prevalence of ACD among users of Free-
StyleTM LibreTM (Abbott Diabetes Care, Witney, Oxfordshire,
UK) has been observed by many dermatologists. In May 2018,
the ANSM (Agence Nationale de Securite du Medicament et des
Produits de Sante) reported that about 0.2% of FreeStyle Libre
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users reported a skin reaction.24 In 2019, a Belgian study
reported that ACD occurred in 5.5% of FreeStyle Libre users.25
Lack of cooperation provided by MD manufacturers in the
diagnostic process
Several papers and communications between colleagues from
all over Europe have revealed the lack of communication
with, and cooperation from, the manufacturers regarding the
qualitative composition of the MDs.26 Surprisingly, despite
numerous requests from the medical profession, reported in
the literature over the last 3 years, manufacturers continue to
refuse collaboration and communication. Due to lack of
cooperation, some medical centres have carried out physico-
chemical analyses, such as gas chromatography–mass spec-
trometry (GC-MS) themselves in order to identify the
sensitizing culprits in medical devices.7,8,10–12 However, such
complicated chromatographic analyses are not available in all
centres. The correct diagnosis (ACD vs. irritant contact der-
matitis) may be delayed or, even worse, missed if patients are
not tested with all relevant allergens. As a result, most
patients remain poorly advised with delays in diagnosis and
management. In the case of glucose sensors, 35% of the
patients reduced the wear time of their medical devices or
stopped using them because of dermatological complica-
tions,27 with significant deterioration of their quality of life.
Due to lack of labelling and lack of information provided by
the manufacturers in case of adverse events, physicians are
limited in their information about safe alternatives.
Analytical techniques such as the one described above do not
provide a guarantee to identify every possible allergen. This
means that in addition to those having been identified, other
sensitizers might also be present, which renders identification of
all possible culprits impossible. Adequate management thus
remains at stake.
Cost of illness to the patients and the society
Skin problems that occur after using MDs also increase the treat-
ment costs. Not only the purchase of new treatments (adhesives,
emollients, protection creams or even topical corticosteroids),
prescribed for prevention or treatment, but also additional fol-
low-up consultations by physicians or dermatologists who per-
form patch testing. For example, a Danish study revealed that
the cost for paediatric patients with skin complications due to
glucose sensor is 154.3 USD higher than patients without skin
problems.28 It should be noted that this price does not take into
account the real costs related to appointments for diabetes
check-ups, visits to the dermatologist, the loss of income for the
patient due to work stoppages and medical consequences of a
poorer control of diabetes. The price for the patient is thus well
underestimated. Moreover, the analytical analyses described
above are very time-consuming and create a considerable cost
for the society as well.
Impact on the quality of life of the patients
Skin reactions due to MDs have been repeatedly reported to
decrease patient quality of life.28 For example, itching due to
the skin complications associated with MDs leads to impaired
concentration, distraction, but also drowsiness owing to
impaired sleep29 and experience additional stress. The patient
is already suffering from a pathology beforehand, for which a
MD has been used; hence, it is often difficult for the patient
to see himself suffering from another problem related to his
medical device. When the problems are dermatological, they
are visible and may affect the patient even more due to
stigmatization. According to some authors, patients perceived
their skin as disfigured.29 The lack of clear information (also
on alternatives) noted above greatly increases the distress of
patients affected by dermatological complications, particularly
ACD.
Severe cases of type I hypersensitivity
While the majority of skin complications secondary to the use of
medical devices are either irritant contact dermatitis or ACD,
there exist rare cases of Type I hypersensitivity as well, such as in
the case of anaphylaxis following the contact with an alginate
dressing.30 Information about the presence of a known allergen
is already important in delayed-type hypersensitivity, but is even
more crucial in the case of potentially life-threatening anaphy-
laxis.
Conclusion
The two new regulations concerning medical devices (Regula-
tion EU 2017/745) and in vitro diagnostic medical devices
(Regulation EU 2017/746) intend to provide better protection
of public health and patient safety. However, they do not
provide a benefit for the prevention and management of
adverse events, such as contact dermatitis. Due to the
increasing number of cases of allergic contact dermatitis from
medical devices leading to deleterious effects on quality of life
of the patients and increasing cost of illness, this gap should
be closed by appropriate specifications in the Q & A docu-
ments produced for implementation of the new Medical
Device Regulation or respectively in an overarching guideline
or an amendment to the Medical Device Regulation. As a
minimum requirement, the following should be specified and
implemented: ‘Labelling needs to include skin (and airway)
sensitizers as identified in CLP (H317) used at any stage in
the production process of the medical device with body con-
tact, with or without drugs included’. It would be preferable
to have full labelling as is the case for cosmetics and pharma-
ceutical products, because some ingredients are not yet recog-
nized as contact sensitizers. Moreover, full cooperation of
manufacturers with the medical community is essential in
case – sometimes even severe – adverse (skin) reactions
occur.
© 2021 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology
JEADV 2021, 35, 1444–1448
The need for EU legislation to require disclosure and labelling 1447
Acknowledgements
We would like to thank Marie Baeck (Department of Dermatol-
ogy, Cliniques universitaires Saint-Luc in Brussels, Belgium),
Mark Wilkinson (Department of Dermatology, Leeds Teaching
Hospitals NHS Trust, in Leed, UK), Marie-Noelle Crepy
(Department of Occupational and Environmental Diseases,
Hotel-Dieu Hospital, Paris, France and Department of Derma-
tology, Cochin Hospital, Paris Descartes University, Paris,
France), and Andreas Bircher (Allergy Unit, Department of Der-
matology, University Hospital Basel, Basel, Switzerland) for their
precious support.
References
1 Regulation (EU) 2017/745 of the European Parliament and of the Council
of 5 April 2017 on medical devices aDE, Regulation (EC) No 178/2002
and Regulation (EC) No 1223/2009 and repealing Council Directives 90/
385/EEC and 93/42/EEC. URL https://eur-lex.europa.eu/legal-content/
EN/TXT/HTML/?uri=CELEX:32017R0745&qid=1617627663915&f
rom=en (last accessed: 15 October 2020).
2 Regulation (EU) 2017/746 of the European Parliament and of the Council
of 5 April 2017 on in vitro diagnostic medical devices and repealing
Directive 98/79/EC and Commission Decision. URL https://eur-lex.euro
pa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32017R0746&from=
EN (last accessed: 10 October 2020).
3 European Commission. Regulatory framework. The new Regulations on
medical devices. URL https://ec.europa.eu/growth/sectors/medical-device
s/regulatory-framework_en (last accessed: 26 June 2019).
4 Regulation (EU) 2020/561 of the European Parliament and of the council
of 23 April 2020 amending Regulation (EU) 2017/745 on medical devices,
as regards the dates of application of certain of its provisions. URL
https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:
32020R0561&from=EN (last accessed: 5 May 2020).
5 Boom BW, van Driel LM. Allergic contact dermatitis to epoxy resin in
infusion sets of an insulin pump. Contact Dermatitis 1985; 12: 280.
6 Schwensen JF, Friis UF, Zachariae C, Johansen JD. Sensitization to
cyanoacrylates caused by prolonged exposure to a glucose sensor set in a
diabetic child. Contact Dermatitis 2016; 74: 124–125.
7 Peeters C, Herman A, Goossens A et al. Allergic contact dermatitis caused
by 2-ethyl cyanoacrylate contained in glucose sensor sets in two diabetic
adults. Contact Dermatitis 2017; 77: 426–129.
8 Herman A, Aerts O, Baeck M et al. Allergic contact dermatitis caused by
isobornyl acrylate in Freestyle(R) Libre, a newly introduced glucose sen-
sor. Contact Dermatitis 2017; 77: 367–373.
9 Corazza M, Scuderi V, Musmeci D et al. Allergic contact dermatitis
caused by isobornyl acrylate in a young diabetic patient using a continous
glucose monitoring system (Freestyle Libre). Contact Dermatitis 2018; 79:
320–321.
10 Kamann S, Aerts O, Heinemann L. Further evidence of severe allergic
contact dermatitis from isobornyl acrylate while using a continuous glu-
cose monitoring system. J Diabetes Sci Technol 2018; 12: 630–633.
11 Raison-Peyron N, Mowitz M, Bonardel N, Aerts O, Bruze M. Allergic
contact dermatitis caused by isobornyl acrylate in OmniPod, an innova-
tive tubeless insulin pump. Contact Dermatitis 2018; 79: 76–80.
12 Mowitz M, Herman A, Baeck M et al. N, N-dimethylacrylamide-a new
sensitizer in the freestyle libre glucose sensor. Contact Dermatitis 2019;
81: 27–31.
13 Passanisi S, Lombardo F, Barbalace A et al. Allergic contact dermatitis
and diabetes medical devices: 2 clinical cases. Contact Dermatitis 2018; 79:
115–117.
14 Mestach L, Huygens S, Goossens A, Gilissen L. Allergic contact dermatitis
caused by acrylic-based medical dressings and adhesives. Contact Der-
matitis 2018; 79: 81–84.
15 Kerre S, Strobbe T, Naessens T et al. Alkyl glucosides: newly identified
allergens in foam wound dressings. Contact Dermatitis 2018; 79: 191–193.
16 Liu T, Wan J, McKenna RA, Jackson OA, Treat JR. Allergic contact der-
matitis caused by Dermabond in a paediatric patient undergoing skin
surgery. Contact Dermatitis 2019; 80: 61–62.
17 Aschenbeck KA, Hylwa SA. A diabetic’s allergy: ethyl cyanoacrylate in
glucose sensor adhesive. Dermatitis 2017; 28: 289–291.
18 Perez Gonzalez EL, Medina Alfaro I, Iglesias Cadarso A, Boteanu C.
An unusual case of contact dermatitis caused by a pacemaker
implanted for neurostimulation. J Investig Allergol Clin Immunol 2017;
27: 272–273.
19 Deswysen AC, Zimerson E, Goossens A, Bruze M, Baeck M. Allergic con-
tact dermatitis caused by self-adhesive electrocardiography electrodes in
an infant. Contact Dermatitis 2013; 69: 379–381.
20 Crepy MN, Lecuen J, Ratour-Bigot C, Stocks J, Bensefa-Colas L. Accelera-
tor-free gloves as alternatives in cases of glove allergy in healthcare work-
ers. Contact Dermatitis 2018; 78: 28–32.
21 Dejonckheere G, Herman A, Baeck M. Allergic contact dermatitis
caused by synthetic rubber gloves in healthcare workers: sensitization
to 1,3-diphenylguanidine is common. Contact Dermatitis 2019; 81:
167–173.
22 Pillsbury ME, Ronkainen S, Goodier M, Hylwa SA. Are rubber gloves
marketed as accelerator-free truly free of accelerators? Dermatitis 2020;
31: 128–133.
23 Nardelli A, D’Hooghe E, Drieghe J, Dooms M, Goossens A. Allergic con-
tact dermatitis from fragrance components in specific topical pharmaceu-
tical products in Belgium. Contact Dermatitis 2009; 60: 303–313.
24 ANSM. (Agence Nationale de Securite du Medicament et des produits de
sante). Point sur les donnees de materiovigilance du dispositif de mesure
du glucose FreeStyle Libre - Point d’Information. URL https://www.
ANSM.sante.fr/S-informer/Points-d-information-Points-d-information/
Point-sur-les-donnees-de-materiovigilance-du-dispositif-de-mesure-du-
glucose-FreeStyle-Libre-Point-d-Information (last accessed: 23 July
2019).
25 Pyl J, Dendooven E, Van Eekelen I et al. Prevalence and prevention of
contact dermatitis caused by FreeStyle Libre: a monocentric experience.
Diabetes Care 2020; 43: 918–920.
26 Heinemann L, Fleming GA, Petrie JR et al. Insulin pump risks and bene-
fits: a clinical appraisal of pump safety standards, adverse event reporting
and research needs. A joint statement of the European Association for the
Study of Diabetes and the American Diabetes Association Diabetes Tech-
nology Working Group. Diabetologia 2015; 58: 862–870.
27 Berg AK, Olsen BS, Thyssen JP et al. High frequencies of dermatological
complications in children using insulin pumps or sensors. Pediatr Dia-
betes 2018; 19: 733–740.
28 Berg AK, Thorsen SU, Thyssen JP et al. Cost of treating skin problems in
patients with diabetes who use insulin pumps and/or glucose sensors.
Diabetes Technol Ther 2020; 22: 658–665.
29 Berg AK, Simonsen AB, Svensson J. Perception and possible causes of
skin problems to insulin pump and glucose sensor: results from pediatric
focus groups. Diabetes Technol Ther 2018; 20: 566–570.
30 McCarthy S, Dvorakova V, O’Sullivan P, Bourke JF. Anaphylaxis caused
by alginate dressing. Contact Dermatitis 2018; 79: 396–397.
© 2021 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology
JEADV 2021, 35, 1444–1448
1448 Herman et al.
